HIV replication is associated with increased severity of liver biopsy changes in HIV-HBV and HIV-HCV co-infection

Journal of Medical Virology

Volumn 84, Issue 7, 2012, Pages 993-1001

  Audsley, Jennifer ^a,b   du Cros, Philipp ^a   Goodman, Zachary ^c   Mclean, Catriona ^a,b   Mijch, Anne ^a,b   Lewin, Sharon R ^a,b,d   Sasadeusz, Joe ^a,e  

^a ALFRED HOSPITAL   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c ARMED FORCES INSTITUTE OF PATHOLOGY   (United States)

^d BURNET INSTITUTE   (Australia)

^e VICTORIAN INFECTIOUS DISEASES REFERENCE LABORATORY   (Australia)

Author keywords

HIV RNA; HIV hepatitis co infection; Liver biopsy; Liver fibrosis

Indexed keywords

DIDANOSINE; HEPATITIS B CORE ANTIBODY; STAVUDINE; VIRUS RNA;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EXPOSURE; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISTOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; INFLAMMATION; LIVER BIOPSY; LIVER FIBROSIS; LIVER NECROSIS; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; SELF REPORT; STEATOSIS; TREATMENT DURATION; VIRUS REPLICATION;

ADULT; BIOPSY; COINFECTION; FEMALE; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HIV; HIV INFECTIONS; HUMANS; LIVER; MALE; MIDDLE AGED; RNA, VIRAL; SEVERITY OF ILLNESS INDEX; VIRAL LOAD;

HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN IMMUNODEFICIENCY VIRUS;

EID: 84861007173     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.23236     Document Type: Article

References (68)

1. Bach N, Theise ND, Schaffner F. 1992. Hepatic histopathology in the acquired immunodeficiency syndrome. Semin Liver Dis 12: 205-212.
2. Balasubramanian A, Ganju RK, Groopman JE. 2003. Hepatitis C virus and HIV envelope proteins collaboratively mediate interleukin-8 secretion through activation of p38 MAP kinase and SHP2 in hepatocytes. J Biol Chem 278: 35755-35766.
3. Benhamou Y, Bochet M, Di Martino V, Charlotte F, Azria F, Coutellier A, Vidaud M, Bricaire F, Opolon P, Katlama C, Poynard T, for the MG. 1999. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. Hepatology 30: 1054-1058.
4. Blanco F, Barreiro P, Ryan P, Vispo E, Martin-Carbonero L, Tuma P, Labarga P, Medrano J, Gonzalez-Lahoz J, Soriano V. 2011. Risk factors for advanced liver fibrosis in HIV-infected individuals: Role of antiretroviral drugs and insulin resistance. J Viral Hepat 18: 11-16.
5. Bonacini M. 1992. Hepatobiliary complications in patients with human immunodeficiency virus infection. Am J Med 92: 404-411.
6. Bräu N, Salvatore M, Ríos-Bedoya CF, Fernández-Carbia A, Paronetto F, Rodríguez-Orengo JF, Rodríguez-Torres M, for the Puerto Rico-New York Hepatitis Study G. 2006. Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. J Hepatol 44: 47-55.
7. Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, Rao S, Kazzaz Z, Bornstein E, Lambotte O, Altmann D, Blazar BR, Rodriguez B, Teixeira-Johnson L, Landay A, Martin JN, Hecht FM, Picker LJ, Lederman MM, Deeks SG, Douek DC. 2006. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 12: 1365-1371.
8. Broder S. 2010. The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic. Antivir Res 85: 1-18.
9. Bruno R, Galastri S, Sacchi P, Cima S, Caligiuri A, DeFranco R, Milani S, Gessani S, Fantuzzi L, Liotta F, Frosali F, Antonucci G, Pinzani M, Marra F. 2010. gp120 Modulates the biology of human hepatic stellate cells: A link between HIV infection and liver fibrogenesis. Gut 59: 513-520.
10. Cacciola I, Pollicino T, Squadrito G, Cerenzia G, Orlando ME, Raimondo G. 1999. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med 341: 22-26.
11. Cao YZ, Friedman-Kien AE, Huang YX, Li XL, Mirabile M, Moudgil T, Zucker-Franklin D, Ho DD. 1990. CD4-independent, productive human immunodeficiency virus type 1 infection of hepatoma cell lines in vitro. J Virol 64: 2553-2559.
12. Cao YZ, Dieterich D, Thomas PA, Huang YX, Mirabile M, Ho DD. 1992. Identification and quantitation of HIV-1 in the liver of patients with AIDS. AIDS 6: 65-70.
13. Carr A, Morey A, Mallon P, Williams D, Thorburn DR. 2001. Fatal portal hypertension, liver failure, and mitochondrial dysfunction after HIV-1 nucleoside analogue-induced hepatitis and lactic acidaemia. Lancet 357: 1412-1414.
14. Colin J, Cazals-Hatem D, Loriot M, Martinot-Peignoux M, Pham B, Auperin A, Degott C, Benhamou J, Erlinger S, Valla D, Marcellin P. 1999. Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men. Hepatology 29: 1306-1310.
15. Cossarizza A, Moyle G. 2004. Antiretroviral nucleoside and nucleotide analogues and mitochondria. AIDS 18: 137-151.
16. Cote HCF, Brumme ZL, Craib KJP, Alexander CS, Wynhoven B, Ting L, Wong H, Harris M, Harrigan PR, O'Shaughnessy MV, Montaner JSG. 2002. Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. New Engl J M 346: 811-820.
17. De Maria N, Colantoni A, Friedlander L, Leandro G, Idilman R, Harig J, Van Thiel DH. 2000. The impact of previous HBV infection on the course of chronic hepatitis C. Am J Gastroenterol 95: 3529-3536.
18. Drake A, Mijch A, Sasadeusz J. 2004. Immune reconstitution hepatitis in HIV and hepatitis B coinfection, despite lamivudine therapy as part of HAART. Clin Infect Dis 39: 129-132.
19. Giannini E, Ceppa P, Botta F, Fasoli A, Romagnoli P, Ansaldi F, Durando P, Risso D, Lantieri PB, Icardi GC, Testa R. 2003. Previous hepatitis B virus infection is associated with worse disease stage and occult hepatitis B virus infection has low prevalence and pathogenicity in hepatitis C virus-positive patients. Liver Int 23: 12-18.
20. Gitto S, Micco L, Conti F, Andreone P, Bernardi M. 2009. Alcohol and viral hepatitis: A mini-review. Dig Liver Dis 41: 67-70.
21. Hong F, Tuyama A, Lee TF, Loke J, Agarwal R, Cheng X, Garg A, Fiel MI, Schwartz M, Walewski J, Branch A, Schecter AD, Bansal MB. 2009. Hepatic stellate cells express functional CXCR4: Role in stromal cell-derived factor-1alpha-mediated stellate cell activation. Hepatology 49: 2055-2067.
22. Housset C, Lamas E, Brechot C. 1990. Detection of HIV1 RNA and p24 antigen in HIV1-infected human liver. Res Virol 141: 153-159.
23. Housset C, Lamas E, Courgnaud V, Boucher O, Girard PM, Marche C, Brechot C. 1993. Presence of HIV-1 in human parenchymal and non-parenchymal liver cells in vivo. J Hepatol 19: 252-258.
24. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, Denk H, Desmet V, Korb G, MacSween RNM. 1995. Histological grading and staging of chronic hepatitis. J Hepatol 22: 696-699.
25. Kim AY, Chung RT. 2009. Coinfection with HIV-1 and HCV-A one-two punch. Gastroenterology 137: 795-814.
26. Konopnicki D, Mocroft A, de Wit S, Antunes F, Ledergerber B, Katlama C, Zilmer K, Vella S, Kirk O, Lundgren JD. 2005. Hepatitis B and HIV: Prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS 19: 593-601.
27. Lascar RM, Gilson RJ, Lopes AR, Bertoletti A, Maini MK. 2003. Reconstitution of hepatitis B virus (HBV)-specific T cell responses with treatment of human immunodeficiency virus/HBV coinfection. J Infect Dis 188: 1815-1819.
28. Lebovics E, Dworkin BM, Heier SK, Rosenthal WS. 1988. The hepatobiliary manifestations of human immunodeficiency virus infection. Am J Gastroenterol 83: 1-7.
29. Lewis JR, Mohanty SR. 2010. Nonalcoholic fatty liver disease: A review and update. Dig Dis Sci 55: 560-578.
30. Lin W, Weinberg EM, Tai AW, Peng LF, Brockman MA, Kim K-A, Kim SS, Borges CB, Shao R-X, Chung RT. 2008. HIV increases HCV replication in a TGF-[beta]1-dependent manner. Gastroenterology 134: 803-811.
31. Lincoln D, Petoumenos K, Dore GJ. 2003. HIV/HBV and HIV/HCV coinfection, and outcomes following highly active antiretroviral therapy. HIV Med 4: 241-249.
32. Lonardo A, Loria P, Adinolfi LE, Carulli N, Ruggiero G. 2006. Hepatitis C and steatosis: A reappraisal. J Viral Hepat 13: 73-80.
33. Macias J, Japon Miguel A, Saez C, Palacios RB, Mira Jose A, Garcia-Garcia Jose A, Merchante N, Vergara S, Lozano F, Gomez-Mateos J, Pineda Juan A. 2005. Increased hepatocyte Fas expression and apoptosis in HIV and hepatitis C virus coinfection. J Infect Dis 192: 1566-1576.
34. Maida I, Nunez M, Rios MJ, Martin-Carbonero L, Sotgiu G, Toro C, Rivas P, Barreiro P, Mura MS, Babudieri S, Garcia-Samaniego J, Gonzalez-Lahoz J, Soriano V. 2006. Severe liver disease associated with prolonged exposure to antiretroviral drugs. J Acquir Immune Defic Syndr 42: 177-182.
35. Martinez E, Blanco JL, Arnaiz JA, Perez-Cuevas JB, Mocroft A, Cruceta A, Marcos MA, Milinkovic A, Garcia-Viejo MA, Mallolas J, Carne X, Phillips A, Gatell JM. 2001. Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy. AIDS 15: 1261-1268.
36. McGovern Barbara H, Ditelberg Jeremy S, Taylor Lynn E, Gandhi Rajesh T, Christopoulos Katerina A, Chapman S, Schwartzapfel B, Rindler E, Fiorino A-M, Zaman MT, Sax Paul E, Graeme-Cook F, Hibberd Patricia L. 2006. Hepatic steatosis is associated with fibrosis, nucleoside analogue use, and hepatitis C virus genotype 3 infection in HIV-seropositive patients. Clin Infect Dis 43: 365-372.
37. Minakari M, Molaei M, Shalmani HM, Alizadeh AHM, Jazi AHD, Naderi N, Shavakhi A, Mashayekhi R, Zali MR. 2009. Liver steatosis in patients with chronic hepatitis B infection: Host and viral risk factors. Eur J Gastroenterol Hepatol 21: 512-516. DOI: 10.1097/MEG.0b013e328326792e
38. Missiha SB, Ostrowski M, Heathcote EJ. 2008. Disease progression in chronic hepatitis C: Modifiable and nonmodifiable factors. Gastroenterology 134: 1699-1714.
39. Monga HK, Rodriguez-Barradas MC, Breaux K, Khattak K, Troisi CL, Velez M, Yoffe B. 2001. Hepatitis C virus infection-related morbidity and mortality among patients with human immunodeficiency virus infection. Clin Infect Dis 33: 240-247.
40. Moyle GJ, Datta D, Mandalia S, Morlese J, Asboe D, Gazzard BG. 2002. Hyperlactataemia and lactic acidosis during antiretroviral therapy: Relevance, reproducibility and possible risk factors. AIDS 16: 1341-1349.
41. Munshi N, Balasubramanian A, Koziel M, Ganju R, Groopman J. 2003. Hepatitis C and human immunodeficiency virus envelope proteins cooperatively induce hepatocytic apoptosis via an innocent bystander mechanism. J Infect Dis 188: 1192-1204.
42. Negro F. 2010. Hepatitis C virus-induced steatosis: An overview. Dig Dis 28: 294-299.
43. Paik YH, Schwabe RF, Bataller R, Russo MP, Jobin C, Brenner DA. 2003. Toll-like receptor 4 mediates inflammatory signaling by bacterial lipopolysaccharide in human hepatic stellate cells. Hepatology 37: 1043-1055.
44. Pascual-Pareja JF, Caminoa A, Larrauri C, Gonzalez-Garcia J, Montes ML, Diez J, Grande M, Arribas JR. 2009. HAART is associated with lower hepatic necroinflammatory activity in HIV-hepatitis C virus-coinfected patients with CD4 cell count of more than 350cells/microl at the time of liver biopsy. AIDS 23: 971-975.
45. Qurishi N, Kreuzberg C, Lüchters G, Effenberger W, Kupfer B, Sauerbruch T, Rockstroh JK, Spengler U. 2003. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet 362: 1708-1713.
46. Rajasuriar R, Booth D, Solomon A, Chua K, Spelman T, Gouillou M, Schlub T, Davenport M, Crowe S, Elliott J, Hoy J, Fairley C, Stewart G, Cameron P, Lewin S. 2010. Biological determinants of immune reconstitution in HIV-infected patients on antiretroviral therapy: The role of IL7/IL-7Rα and microbial translocation. J Infect Dis 202: 1254-1264.
47. Rodríguez-Torres M, Govindarajan S, Solá R, Clumeck N, Lissen E, Pessôa M, Buggisch P, Main J, DePamphilis J, Dieterich DT. 2008. Hepatic steatosis in HIV/HCV co-infected patients: Correlates, efficacy and outcomes of anti-HCV therapy: A paired liver biopsy study. J Hepatol 48: 756-764.
48. Seki E, De Minicis S, Osterreicher CH, Kluwe J, Osawa Y, Brenner DA, Schwabe RF. 2007. TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat Med 13: 1324-1332.
49. Serfaty L, Lemoine M. 2008. Definition and natural history of metabolic steatosis: Clinical aspects of NAFLD, NASH and cirrhosis. Diabetes Metab 34: 634-637.
50. Sherman KE, Rouster SD, Chung RT, Rajicic N. 2002. Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: A cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis 34: 831-837.
51. Shoji K, Shuhei N, Kazuhiro H, Hiromu T, Tadashi T, Hiroyuki H, Taichi S, Takatsugu Y, Takashi I, Hiroaki K. 1999. Clinical significance of prior hepatitis B virus infection in patients with hepatitis C virus-related hepatocellular carcinoma. Cancer 86: 793-798.
52. Sterling RK, Contos MJ, Smith PG, Stravitz RT, Luketic VA, Fuchs M, Shiffman ML, Sanyal AJ. 2008. Steatohepatitis: Risk factors and impact on disease severity in human immunodeficiency virus/hepatitis C virus coinfection. Hepatology 47: 1118-1127.
53. Sulkowski M, Thomas D, Chaisson R, Moor R. 2000. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. J Am Med Assoc 283: 74-80.
54. Sulkowski MS, Mehta SH, Torbenson MS, Higgins Y, Brinkley SC, de Oca RM, Moore RD, Afdhal NH, Thomas DL. 2007. Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults. AIDS 21: 2209-2216.
55. Thio CL. 2009. Hepatitis B and human immunodeficiency virus coinfection. Hepatology 49: S138-S145.
56. Thio CL, Seaberg EC, Skolasky R, Jr., Phair J, Visscher B, Munoz A, Thomas DL. 2002. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 360: 1921-1926.
57. Thomas DL, Cannon RO, Shapiro CN, Hook EW III, Alter MJ, Quinn TC. 1994. Hepatitis C, hepatitis B, and human immunodeficiency virus infections among non-intravenous drug-using patients attending clinics for sexually transmitted diseases. J Infect Dis 169: 990-995.
58. Thomas DL, Shih JW, Alter HJ, Vlahov D, Cohn S, Hoover DR, Cheung L, Nelson KE. 1996. Effect of human immunodeficiency virus on hepatitis C virus infection among injecting drug users. J Infect Dis 174: 690-695.
59. Thomopoulos KC, Arvaniti V, Tsamantas AC, Dimitropoulou D, Gogos CA, Siagris D, Theocharis GJ, Labropoulou-Karatza C. 2006. Prevalence of liver steatosis in patients with chronic hepatitis B: A study of associated factors and of relationship with fibrosis. Eur J Gastroenterol Hepatol 18: 233-237.
60. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-Garcia J, Lazzarin A, Carosi G, Sasadeusz J, Katlama C, Montaner J, Sette H, Jr., Passe S, De Pamphilis J, Duff F, Schrenk UM, Dieterich DT. 2004. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. New Engl J Med 351: 438-450.
61. UNAIDS. 2008. The 2008 Report on the global AIDS epidemic. Geneva, Switzerland: UNAIDS.
62. Verma S, Goldin RD, Main J. 2008. Hepatic steatosis in patients with HIV-hepatitis C virus coinfection: Is it associated with antiretroviral therapy and more advanced hepatic fibrosis? BMC Res Notes 1: 46.
63. Vlahakis SR, Villasisâ Keever A, Gomez TS, Bren GD, Paya Carlos V. 2003. Human immunodeficiency virus-induced apoptosis of human hepatocytes via CXCR4. J Infect Dis 188: 1455-1460.
64. Weber R, Sabin CA, Friis-Moller N, Reiss P, El-Sadr WM, Kirk O, Dabis F, Law MG, Pradier C, De Wit S, Akerlund B, Calvo G, Monforte A, Rickenbach M, Ledergerber B, Phillips AN, Lundgren JD. 2006. Liver-related deaths in persons infected with the human immunodeficiency virus: The D:A:D study. Arch Intern Med 166: 1632-1641.
65. Woerle HJ, Mariuz PR, Meyer C, Reichman RC, Popa EM, Dostou JM, Welle SL, Gerich JE. 2003. Mechanisms for the deterioration in glucose tolerance associated with HIV protease inhibitor regimens. Diabetes 52: 918-925.
66. Yip WW, Burt AD. 2006. Alcoholic liver disease. Semin Diagn Pathol 23: 149-160.
67. You M, Fischer M, Deeg MA, Crabb DW. 2002. Ethanol induces fatty acid synthesis pathways by activation of sterol regulatory element-binding protein (SREBP). J Biol Chem 277: 29342-29347.
68. Yu MC, Yuan J, Ross RK, Govindarajan S. 1997. Presence of antibodies to the hepatitis B surface antigen is associated with an excess risk for hepatocellular carcinoma among non-Asians in Los Angeles County, California. Hepatology 25: 226-228.